ClinicalTrials.Veeva

Menu

A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

Novartis logo

Novartis

Status and phase

Completed
Phase 2

Conditions

Asthma

Treatments

Drug: Placebo
Drug: FTY720

Study type

Interventional

Funder types

Industry

Identifiers

NCT00785083
CFTY720D2102

Details and patient eligibility

About

This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma

Enrollment

36 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Forced Expiratory Volume in 1 second of at least 60%
  • History of asthma for at least 6 months
  • Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)

Exclusion criteria

  • History of lung disease other than asthma
  • Smokers
  • Use of inhaled corticosteroid above specified dose
  • Use of oral beta agonists or corticosteroids or other asthma medications
  • Hypersensitivity to the drug
  • Respiratory tract infections within 1 month of the study

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

36 participants in 2 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: FTY720
2
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems